

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. MBHB02-325-A (400/047)	Serial No. 10/712,633
1 st SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Pavco et al.	
		Filing Date: November 13, 2003	Group: 1635



FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	*	WO 97/15662	05/01/97	WO (Pavco et al.)				
	1.	WO 03/070910	08/28/03	WO (McSwiggen et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	2.	Reviewed document, But search report is not considered Non-Patent Literature above European Search Report from EP 02752028 mailed October 8, 2004
	3.	Parrish, "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," <u>Molecular Cell</u> 6:1077-1087 (2000)
	*	McLaren, "Vascular Endothelial Growth Factor and Endometriotic Angiogenesis," <u>Human Reproduction Update</u> 6:45-55 (2000)
	*	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <u>Nature</u> 411:494-498 (2001)

EXAMINER		DATE CONSIDERED	11-07-05
----------	--	-----------------	----------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.


02-325-A (400/047)

Serial No.

10/712,633

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)



Applicant:

Pavco et al.

Filing Date:

November 13, 2003

Group:

1635

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	1.	03/070887	08/28/03	WO (McSwiggen et al.)	_____	_____		
	2.	03/070896	08/28/03	WO (McSwiggen et al.)	_____	_____		
	3.	03/074654	09/12/03	WO (McSwiggen et al.)	_____	_____		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

Reviewed but not considered
NPL

	4.	International Search Report for PCT/US2004/027403 mailed July 12, 2005
	5.	Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> , 18:307-319 (2000)
	6.	Kuwabara et al., "A C. elegans patched gene, ptc-1, functions in germ-line cytokinesis," <i>Genes and Development</i> , 14(15):1933-1944 (2000)

EXAMINER

DATE CONSIDERED

11-07-05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant:	
		Pavco et al.	
		Filing Date:	Group:
		November 13, 2003	1635



U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	*	US 2003/0190635	10/2003	McSwiggen et al.	 	 	
	*	US 2003/0206887	11/2003	Morrissey et al.	 	 	

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	5,814,620	09/28/98	Robinson et al.	 	 	
	*	5,998,203	12/1999	Matulic-Adamic et al.	 	 	
	*	6,506,559	01/14/03	Fire et al.	 	 	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	1.	2,359,180	03/08/00	CA (Kreutzer et al.)	 	 	 	
	2.	1325955	07/09/03	EP (Klippel-Giese et al.)	 	 	 	


EXAMINER		DATE CONSIDERED	11-07-05
----------	--	-----------------	----------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Pavco et al.	
		Filing Date: November 13, 2003	Group: 1635

Copy - Was not provided by Applicants.

33	08208687	08/1996	JP (Hotoda et al.)				
3.	90/14090	11/29/90	WO (Gillespie et al.)				
4.	94/01550	01/20/94	WO (Agrawal et al.)				
5.	97/21808	06/19/97	WO (Robinson)				
6.	99/49029	09/30/99	WO (Graham et al.)				
7.	00/49035	08/24/00	WO (Sheen et al.)				
8.	01/097850	12/27/01	WO (Siemeister et al.)				
9.	01/96584	12/20/01	WO (Mushegian et al.)				
10.	02/07747	01/31/02	WO (King)				
11.	02/10378	02/07/02	WO (Cowser et al.)				
12.	02/22636	03/21/02	WO (Bennett et al.)				
13.	03/068797	08/21/03	WO (Rossi et al.)				
14.	03/070910	08/28/03	WO (McSwiggen et al.)				
15.	03/080638	10/02/03	WO (Lacasse et al.)				
16.	04/009769	01/29/04	WO (Tolentino et al.)				
17.	04/043977	05/27/04	WO (Prakush et al.)				
18.	04/072261	08/26/04	WO (Li et al.)				


EXAMINER 	DATE CONSIDERED 11-7-05
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		02-325-A (400/047)	10/712,633
		Applicant:	
		Pavco et al.	
		Filing Date:	Group:
		November 13, 2003	1635


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).


19.	Anderson et al., "Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance," <i>Oligonucleotides</i> , 13:303-312 (2003)
34.	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglyceryl derivatives of (2'-5')oligo(adenylate)," <i>Eur. J. Biochem.</i> , 142(29):291-298 (1984)
20.	Elbashir et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in <i>Drosophila Melanogaster</i> Embryo Lysate," <i>The EMBO Journal</i> 20:6877-6888 (2001)
21.	Futami et al., "Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2," <i>Nucleic Acids Research Supplement</i> , 251-252 (2002)
22.	International Search Report for PCT/US02/17074 mailed November 12, 2002
23.	International Search Report for PCT/US03/05022 mailed January 6, 2005
24.	International Search Report for PCT/US03/05028 mailed October 17, 2003
25.	International Search Report for PCT/US03/05346 mailed October 17, 2003
26.	International Search Report for PCT/US2004/016390 mailed March 31, 2005
27.	International Search Report for PCT/US2004/030488 mailed January 12, 2005
28.	Leirdal et al., "Gene silencing in mammalian cells by preformed small RNA duplexes," <i>Biochemical and Biophysical Research Communications</i> , 295, 744-748 (2002)
29.	Lin et al., "A Novel mRNA-crRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <i>Biochemical and Biophysical Research Communications</i> , 281, 639-644 (2001)
35.	Lu et al., "Tumor Inhibition By RNAi-Mediated VEGF an VEGFR2 Down Regulation in Xenograft Models," <i>Cancer Gene Therapy</i> , 10, Suppl. 1, S4-S5 (2003)
30.	Parry et al. 1999. "Bioactivity of anti-angiogenic ribozymes targeting <i>Flt-1</i> and <i>KDR</i> mRNA," <i>Nucleic Acid Res.</i> 27:2569-77.
31.	Tuschl et al., "Small Interfering RNAs: A Revolutionary Tool for Analysis of Gene Function and Gene Therapy," <i>Molecular Interventions</i> , 295, 3, 158-167 (2002)

EXAMINER		DATE CONSIDERED	11-07-05
----------	---	-----------------	----------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant:	
		Pavco et al.	
		Filing Date:	Group:
		November 13, 2003	1635

	32.	Tuschl, "RNA Interference and Small Interfering RNAs," <u>Chembiochem</u> 2:239-245 (2001)
--	-----	--

EXAMINER		DATE CONSIDERED	11-07-05
----------	---	-----------------	----------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-325-A (400/047)

Serial No.

10/712,633

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Pavco et al.

Filing Date:

November 13, 2003

Group:

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Publication Date if Appropriate
<i>JK</i>	*	08/584,040	01/11/96	Pavco et al.			
	*	08/878,640	07/19/97	Usman et al.			
	*	09/205,520	12/03/98	Sullenger et al.			
	*	09/301,511	04/28/99	Beigelman et al.			
	*	09/371,772	08/10/99	Pavco et al.			
	*	09/476,387	12/30/99	Beigelman et al.			
	*	09/708,690	11/07/00	Pavco et al.			
	*	09/870,161	05/29/01	Pavco et al.			
	*	09/877,526	06/08/01	Usman et al.			
	*	09/918,728	07/31/01	Beigelman et al.			
	*	10/138,674	05/03/02	Pavco et al.			
	*	60/005,974	10/26/95	Pavco et al.			
	*	60/082,404	04/20/98	Thomson et al.			
	*	60/101,174	09/21/98	Hartmann et al.			
	*	60/334,461	11/30/01	Sandberg et al.			

U.S. PATENT DOCUMENTS

EXAMINER	<i>Jeff. E. Ford</i>	DATE CONSIDERED	<i>11-7-05</i>
----------	----------------------	-----------------	----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-325-A (400/047)

Serial No.

10/712,633

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



Applicant:

Pavco et al.

Filing Date:

November 13, 2003

Group:

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	4,987,071	01/22/91	Cech et al.			
	*	5,270,163	12/14/93	Gold et al.			
	*	5,334,711	08/02/94	Sproat et al.			
	*	5,475,096	12/12/95	Gold et al.			
	*	5,525,468	06/11/96	McSwiggen et al.			
	*	5,589,332	12/31/96	Shih et al.			
	*	5,624,803	04/29/97	Noonberg et al.			
	*	5,631,359	05/20/97	Chowrira et al.			
	*	5,670,633	09/23/97	Cook et al.			
	*	5,627,053	05/06/97	Usman et al.			
	*	5,672,695	09/30/97	Eckstein et al.			
	*	5,716,824	02/10/98	Beigelman et al.			
	*	5,741,679	04/21/98	George et al.			
	*	5,792,847	08/11/98	Buhr et al.			
	*	5,807,718	09/15/98	Joyce et al.			
	*	5,834,186	11/10/98	George et al.			
	*	5,849,902	12/15/98	Arrow et al.			

EXAMINER

DATE CONSIDERED

11-07-05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-325-A (400/047)

Serial No.

10/712,633

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

Pavco et al.

Filing Date:

November 13, 2003

Group:

<i>JK</i>	*	5,854,038	12/29/98	Sullenger and Cech					
	*	5,871,914	02/16/99	Nathan et al.					
	*	5,898,031	04/27/99	Crooke					
	*	5,989,912	11/23/99	Arrow et al.					
	*	6,001,311	12/14/99	Brennan					
	*	6,005,087	12/21/99	Cook et al.					
	*	6,107,094	08/22/00	Crooke					
	*	6,127,173	10/03/00	Eckstein et al.					
	*	6,159,714	12/12/00	Usman et al.					
	*	6,180,613	01/30/01	Kaplitt et al.					
	*	6,300,074	10/09/01	Gold et al.					
	*	6,346,398	02/12/02	Pavco et al.					
	*	6,476,205	11/05/02	Buhr et al.					
<i>JK</i>	*	6,566,127	05/20/03	Pavco et al.					

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No


EXAMINER


DATE CONSIDERED

Jan H. Eysen Ford
11-0705

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Pavco et al.	
		Filing Date: November 13, 2003	Group:

	*	360257	03/28/90	EP (Hampel et al.)				
	*	89/02439	03/23/89	WO (Arnold et al.)				
	*	91/03162	03/21/91	WO (Rossi et al.)				
	*	92/07065	09/23/91	WO (Eckstein et al.)				
	*	93/15187	08/05/93	WO (Usman et al.)				
	*	93/23057	11/25/93	WO (Thompson et al.)				
	1.	93/23569	11/25/93	WO (Draper et al.)				
	*	94/02595	02/03/94	WO (Sullivan et al.)				
	*	95/04142	02/09/95	WO (Robinson)				
	*	95/04818	02/16/95	WO (Draper et al.)				
	*	95/06731	03/09/95	WO (Usman et al.)				
	*	95/11304	Ck date	WO (Usman et al.)				
	*	95/11910	05/04/95	WO (Dudycz et al.)				
	*	95/13380	05/18/95	WO (Draper et al.)				
	*	95/21868	08/17/95	WO (Rockwell et al.)				
	*	95/23225	08/31/95	WO (Stinchcomb et al.)				
	*	96/10390	04/11/96	WO (Asnell et al.)				
	*	96/10391	04/11/96	WO (Holland et al.)				

EXAMINER 	DATE CONSIDERED 11-7-05
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Pavco et al.	
		Filing Date: November 13, 2003	Group:

	*	96/10392	04/11/96	WO (Choi et al.)						
	2.	96/18736	06/20/96	WO (Beigelman et al.)						
	*	96/22689	08/01/96	WO (Pyle et al.)						
	3.	97/15662	05/01/97	WO (Pavco et al.)						
	*	97/26270	07/04/97	WO (Wincott et al.)						
	*	98/13526	04/02/98	WO (Woolf et al.)						
	*	98/27104	06/25/98	WO (Breaker et al.)						
	*	98/28317	07/02/98	WO (Karpeisky et al.)						
	4.	98/43993	03/30/98	WO (Breaker et al.)						
	*	98/58058	12/23/98	WO (Ludwig et al.)						
	5.	99/04819	02/04/99	WO (Klimuk et al.)						
	6.	99/05094	02/04/99	WO (Beigelman et al.)						
	7.	99/07409	02/18/99	WO (Deschamps de Paillette et al.)						
	8.	99/14226	09/14/98	WO (Wengel et al.)						
	*	99/16871	04/08/99	WO (Eckstein et al.)						
	9.	99/32619	07/01/99	WO (Fire et al.)						
	10.	99/49029	09/30/99	WO (Graham et al.)						
	11.	99/53050	10/21/99	WO (Waterhouse et al.)						
	12.	99/54459	10/28/99	WO (Thompson et al.)						

EXAMINER 	DATE CONSIDERED 11-07-05
---	---------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-325-A (400/047)

Serial No.

10/712,633

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Pavco et al.

Filing Date:

November 13, 2003

Group:

	*	99/55857	11/04/99	WO (Beigelman et al.)					
	13.	99/61631	12/02/99	WO (Heifetz et al.)					
	14.	99/63116	12/09/99	WO (Storella et al.)					
	15.	00/01846	01/13/00	WO (Plaetinck et al.)					
	*	00/24931	05/04/00	WO (Nathan et al.)					
	*	00/26226	05/11/00	WO (Breaker et al.)					
	16.	00/44895	08/03/00	WO (Kreutzer et al.)					
	17.	00/44914	08/03/00	WO (Li et al.)					
	18.	00/63364	10/26/00	WO (Pachuk et al.)					
	19.	00/66604	05/04/00	WO (Wengel et al.)					
	20.	00/73416	12/07/00	WO (Labarbera et al.)					
	21.	01/29058	04/26/01	WO (Mello and Fire)					
	22.	01/32920	05/10/01	WO (Pappa)					
	23.	01/36646	05/25/01	WO (Zernicka-Goetz et al.)					
	24.	01/75164	10/11/01	WO (Tuschl et al.)					
	25.	02/096927 (PCT/US02/17674)	12/05/02	Escobedo et al.					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	*	Aiello et al., "Suppression of Retinal Neovascularization <i>in vivo</i> by Inhibition of Vascular Endothelial Growth Factor (VEGF) Using Soluble VEGF-Receptor Chimeric Proteins,"
--	---	---


→ cont. on next page

EXAMINER		DATE CONSIDERED	11-7-05
----------	--	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Pavco et al.	
		Filing Date: November 13, 2003	Group:


JH		Proc. Natl. Acad. Sci. USA 92: 10457-10461 (1995)
	*	Aiello, <i>et al.</i> , "Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders," 1994 <i>New Engl. J. Med.</i> 331, 1480
	*	Akhtar and Juliano, "Cellular Uptake and Intracellular Fate of AntiSense Oligonucleotides," <i>Trends Cell Biol.</i> 2:139-144 (1992)
	26.	Aldrian-Herrada <i>et al.</i> , "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a <i>retro-inverso</i> delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," <i>Nucleic Acids Research</i> 26:4910-4916 (1998)
	27.	Bahramian <i>et al.</i> , "Transcriptional and Posttranscriptional Silencing of Rodent $\alpha 1(I)$ Collagen by a Homologous Transcriptionally Self-Silenced Transgene," <i>Molecular and Cellular Biology</i> , 274-283 (1999)
	*	Bartel and Szostak, "Isolation of New Ribozymes From a Large Pool of Random Sequences," <i>Science</i> 261:1411-1418 (1993)
	28.	Bass, "The short answer," <i>Nature</i> 411:428-429 (2001)
	*	Beaucage and Iyer, "The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives," <i>Tetrahedron</i> 49:1925-1963 (1993)
	29.	Beaudry and Joyce, "Directed Evolution of an RNA Enzyme," <i>Science</i> 257:635-641 (1992)
	*	Beigelman <i>et al.</i> , "Chemical Modification of Hammerhead Ribozymes," <i>J. Biol. Chem.</i> 270:25702-25708 (1995)
	30.	Bellon <i>et al.</i> , "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," <i>Nucleosides & Nucleotides</i> 16:951-954 (1997)
	31.	Bellon <i>et al.</i> , "Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid Phase Synthesis," <i>Bioconjugate Chem.</i> 8:204-212 (1997)
JH	32.	Berzal-Herranz <i>et al.</i> , "Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme," <i>EMBO J.</i> 12:2567-2574 (1993)

EXAMINER 	DATE CONSIDERED 11-7-05
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant:		
(Use several sheets if necessary)		Pavco et al.		
Filing Date:		Group:		
November 13, 2003				


33.	Blesch, "Delivery of Neurotrophic Factors to Neuronal Targets: Toward Gene Therapy in the CNS," <i>Drug News & Perspectives</i> 13:269-280 (2000)
34.	Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <i>Journal of Pharmaceutical Sciences</i> 87:1308-1315 (1998)
35.	Boado, "Antisense drug delivery through the blood-brain barrier," <i>Advanced Drug Delivery Reviews</i> 15:73-107 (1995)
*	Breaker and Joyce, "Inventing and improving ribozyme function: rational design versus iterative selection methods," <i>TIBTECH</i> 12:268-275 (1994)
*	Breaker et al., "A DNA enzyme with Mg ²⁺ -dependent RNA phosphoesterase activity," <i>Chemistry & Biology</i> 2(10):655-660 (1995)
* /	Breaker, "Are engineered proteins getting competition from RNA?" <i>Current Opinion in Biotechnology</i> 7:442-448 (1996)
36.	Breaker, "Catalytic DNA: in training and seeking employment," <i>Nature Biotechnology</i> 17:422-423 (1999)
37.	Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis," <i>Biotechnology and Bioengineering (Combinatorial Chemistry)</i> 61:33-45 (1998)
38.	Brody and Gold, "Aptamers as therapeutic and diagnostic agents," <i>Reviews in Molecular Biotechnology</i> 74:5-13 (2000)
39.	Brogniez et al., "Fluorescence of Experimented Endometriosis in Rabbits, Using Tamoxifen-eosin Association," <i>Human Reproduction</i> 10:927-931 (1995)
*	Burger et al., "Experimental Corneal Neovascularization: Biomicroscopic, Angiographic, and Morphologic Correlation," <i>Cornea</i> 4:35-41 (1985/1986)
*	Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," <i>Biochemistry</i> 35:14090-14097 (1996) (volume no mistakenly listed as 6)

EXAMINER 	DATE CONSIDERED 11-7-05
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Pavco et al.	
		Filing Date: November 13, 2003	Group:

40.	Burlina et al., "Chemical Engineering of RNase Resistant and Catalytically Active Hammerhead Ribozymes," <i>Bioorganic & Medicinal Chemistry</i> 5:1999-2010 (1997).
*	Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," <i>Methods in Enzymology</i> 211:3-19 (1992)
*	Cech, "Ribozymes and Their Medical Implications," <i>JAMA</i> 260:3030-3034 (1988)
*	Chartrand et al., "An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain," <i>Nucleic Acids Research</i> 23(20):4092-4096 (1995)
*	Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates," <i>Nucleic Acids Research</i> 20:4581-4589 (1992)
*	Chowrira et al., "In Vitro and in Vivo Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes," <i>J. Biol. Chem.</i> 269:25856-25864 (1994)
*	Christoffersen and Marr, "Ribozymes as Human Therapeutic Agents," <i>J. Med. Chem.</i> 38:2023-2037 (1995) (also referred to as Christofferson and Marr)
41.	Christoffersen et al., "Application of computational technologies to ribozyme biotechnology products," <i>Journal of Molecular Structure (Theochem)</i> 311:273-284 (1994) (maybe referred to as Christofferson)
*	Cload and Schepartz, "Polyether Tethered Oligonucleotide Probes," <i>J. Am. Chem. Soc.</i> 113:6324-6326 (1991)
*	Collins and Olive, "Reaction Conditions and Kinetics of Self-Cleavage of a Ribozyme Derived From <i>Neurospora</i> VS RNA," <i>Biochemistry</i> 32:2795-2799 (1993)
42.	Couture and Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function," <i>Trends In Genetics</i> 12:510-515 (1996)
43.	Crooke, "Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides," <i>Advances in Pharmacology</i> 40:1-49 (1997)

EXAMINER 	DATE CONSIDERED 11-7-05
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
		Applicant: Pavco et al.	
		Filing Date: November 13, 2003	Group:

44.	Crooke, "Antisense Therapeutics," <u>Biotechnology and Genetic Engineering Reviews</u> 15:121-157 (1998)
45.	Crooke, "Progress in Antisense Technology: The End of the Beginning," <u>Methods in Enzymology</u> 313:3-45 (1999)
46.	Cummings and Metcalf, "Effect of Surgically Induced Endometriosis on Pregnancy and Effect of Pregnancy and Lactation on Endometriosis in Mice ¹ " <u>P.S.E.B.M.</u> 212:332-337 (1996)
47.	Cummings et al., "Promotion of Endometriosis by 2,3, 7, 8-Tetrachlorodibenzo- <i>p</i> -dioxin in Rats and Mice: Time-Dose Dependence and Species Comparison ^{1,2} " <u>Toxicology and Applied Pharmacology</u> 138:131-139 (1996)
48.	D'Hooghe et al., "The Cycle Pregnancy Rate is Normal in Baboons with Stage I Endometriosis but Decreased in Primates with Stage II and Stage III-IV Disease," <u>Fertility and Sterility</u> 66:809-813 (1996)
49.	Delihias et al., "Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design," <u>Nature Biotechnology</u> 15:751-753 (1997)
*	Detmar et al., "Overexpression of Vascular Permeability Factor/Vascular Endothelial Growth Factor and its Receptors in Psoriasis," 1994 <u>J. Exp. Med.</u> 180, 1141
50.	Donnez et al., "Vascular Endothelial Growth Factor (VEGF) in Endometriosis," <u>Human Reproduction</u> 13:1686-1690 (1998)
*	Dreyfus, "Restriction Ribozymes?" <u>Einstein Quarterly Journal of Biology and Medicine</u> 6:92-93 (1988)
*	Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," <u>Journal of Virology</u> 66:1432-1441 (1992)
*	Durand et al., "Circular Dichroism Studies of an Oligodeoxyribonucleotide Containing a Hairpin Loop Made of a Hexaethylene Glycol Chain: Conformation and Stability," <u>Nucleic Acids Research</u> 18:6353-6359 (1990)

EXAMINER <i>Janet H. Egan - Ford</i>	DATE CONSIDERED 11-07-05
---	---------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Pavco et al.	
		Filing Date: November 13, 2003	Group:


	*	Duval-Valentin, "Specific inhibition of transcription by triple helix-forming oligonucleotides," <u>Proc. Natl. Acad. Sci. USA</u> 89:504-508 (1992)
51.		Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," <u>Biopolymers</u> 48:39-55 (1998)
	*	Egholm et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," <u>Nature</u> 365:566-568 (1993)
52.		Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <u>Nature</u> 411:494-498 (2001)
53.		Elkins and Rossi, "Ch. 2 - Cellular Delivery of Ribozymes," in <u>Delivery Strategies for Antisense Oligonucleotide Therapeutics</u> , edited by Akhtar, CRC Press, pp. 17-220 (1995)
*		Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells," <u>Proc. Natl. Acad. Sci. USA</u> 87:6743-6747 (1990)
54.		Genbank Accession no. X51602
55.		Emerich et al., "Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted Into the Brain," <u>Cell Transplantation</u> 8:47-58 (1999)
56.		Fasciani et al., "High Concentrations of the Vascular Endothelial Growth Factor and Interleukin-8 in Ovarian Endometriomata," <u>Molecular Human Reproduction</u> 6:50-54 (2000)
*		Fava et al., "Vascular Permeability Factor/Endothelial Growth Factor (VPF/VEGF): Accumulation and Expression in Human Synovial Fluids and Rheumatoid Synovial Tissue," 1994 <u>J. Exp. Med.</u> 180, 341
*		Feldstein et al., "Two sequences participating in the autolytic processing of satellite tobacco ringspot virus complementary RNA," <u>Gene</u> 82:53-61 (1989)
	*	Ferentz and Verdine, "Disulfied Cross-Linked Oligonucleotides," <u>J. Am. Chem. Soc.</u> 113:4000-4002 (1991)

EXAMINER 	DATE CONSIDERED 11-7-05
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Pavco et al.	
		Filing Date: November 13, 2003	Group:


JL	*	Ferrara, "Vascular Endothelial Growth Factor," 1993 <i>Trends Cardiovas. Med.</i> 3, 2244
	57.	Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in <i>Caenorhabditis Elegans</i> ," <i>Nature</i> 391:806-811 (1998)
	*	Folkman and Shing, "Angiogenesis," <i>J. Biol. Chem.</i> 267:10931-10934 (1992)
	58.	Folkman et al., "Long-term Culture of Capillary Endothelial Cells," <i>Proc. Natl. Acad. Sci. USA</i> 76:5217-5221 (1979)
	*	Folkman, "What is the Evidence that Tumors are Angiogenesis Dependent?" <i>Journal of the National Cancer Institute</i> 82:4-6 (1990)
	*	Folkman, "Tumor Angiogenesis" 1985 <i>Adv. Cancer. Res.</i> 43, 175
	*	Fong et al., "Role of the Flt-1 Receptor Tyrosine Kinase in Regulating the Assembly of Vascular Endothelium," 1995 <i>Nature</i> 376, 66 Corrected from specification
	*	Forster and Altman, "External Guide Sequences for an RNA Enzyme," <i>Science</i> 249:783-786 (1990)
	59.	Fox, "Targeting DNA with Triplexes," <i>Current Medicinal Chemistry</i> 7:17-37 (2000)
	*	Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," <i>Proc. Natl. Acad. Sci. USA</i> 83:9373-9377 (1986) [sometimes referred to as Frier]
	*	Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," <i>Nucleic Acids Research</i> 21:2867-2872 (1993)
	60.	Genbank Accession No. NM_002019
	61.	Genbank Accession No. NM_002253
	62.	Genbank Accession No. NM_003376
	*	Gitay-Goren et al., "The Binding of Vascular Endothelial Growth Factor to Its Receptor is Dependent on Cell Surface-associated Heparin-like Molecules," 1992 <i>J. Biol. Chem.</i> 267, 6093
JL	*	Gold et al., Diversity of Oligonucleotide Functions," <i>Annu. Rev. Biochem.</i> 64:763-797 (1995)

EXAMINER 	DATE CONSIDERED 11-7-05
---	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant:	
		Pavco et al.	
		Filing Date:	Group:
		November 13, 2003	

63.	Gold, "Axonal Regeneration of Sensory Nerves is Delayed by Continuous Intrathecal Infusion of Nerve Growth Factor," <i>Neuroscience</i> 76:1153-1158 (1997)
64.	Good et al., "Expression of small, therapeutic RNAs in human nuclei," <i>Gene Therapy</i> 4:45-54 (1997)
*	Grant et al., "Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor," <i>Diabetologia</i> 36:282-291 (1993)
*	Griffin et al., "Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2'-hydroxyl groups," <i>Chemistry & Biology</i> 2:761-770 (1995)
65.	Groothuis and Levy, "The entry of antiviral and antiretroviral drugs into the central nervous system," <i>Journal of NeuroVirology</i> 3:387-400 (1997)
*	Guerrier-Takada et al., "The RNA Moiety of Ribonuclease P Is the Catalytic Subunit of the Enzyme," <i>Cell</i> 35:849-857 (1983)
66.	Guo and Collins, "Efficient <i>trans</i> -cleavage of a stem-loop RNA substrate by a ribozyme derived from <i>Neurospora</i> VS RNA," <i>EMBO J.</i> 14:368-376 (1995)
67.	Hagihara et al., "Widespread gene transfection into the central nervous system of primates," <i>Gene Therapy</i> 7:759-763 (2000)
68.	Hamilton, et al., "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants," <i>Science</i> , 286, 950-952 (1999)
69.	Hammann et al., "Length Variation of Helix III in a Hammerhead Ribozyme and Its Influence on Cleavage Activity," <i>Antisense & Nucleic Acid Drug Development</i> 9:25-31 (1999)
*	Hampel and Tritz, "RNA Catalytic Properties of the Minimum (-)sTRSV Sequence," <i>Biochemistry</i> 28:4929-4933 (1989)
*	Hampel et al., "'Hairpin' Catalytic RNA Model: Evidence for Helices and Sequence Requirement for Substrate RNA," <i>Nucleic Acids Research</i> 18:299-304 (1990)

EXAMINER		DATE CONSIDERED	11-7-05
----------	---	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-325-A (400/047)

Serial No.

10/712,633

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:


Pavco et al.

Filing Date:

November 13, 2003

Group:

*	Haseloff and Gerlach, "Sequences required for self-catalysed cleavage of the satellite RNA of tobacco ringspot virus," <u>Gene</u> 82:43-52 (1989)
*	Haseloff and Gerlach, "Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities," <u>Nature</u> 334:585-591 (1988)
70.	Hermann and Patel, "Adaptive Recognition by Nucleic Acid Aptamers," <u>Science</u> 287:820-825 (2000)
71.	Herrlinger et al., "HSV-1 Vectors for Gene Therapy of Experimental CNS Tumors," <u>Methods Mol. Med.</u> 35:287-312 (2000)
*	Hertel et al., "Numbering System for the Hammerhead," <u>Nucleic Acids Research</u> 20:3252 (1992)
72.	Ho et al., "Antisense Oligonucleotides for Target Validation in the CNS," <u>Current Opinion in Molecular Therapeutics</u> 1:336-343 (1999)
73.	Hunziker et al., "Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods," <u>VCH</u> , 331-417 (1995)
*	Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," <u>Chem. Pharm. Bull.</u> 43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)
*	Ishizaka et al., "Isolation of Active Ribozymes from an RNA Pool of Random Sequences Using an Anchored Substrate RNA," <u>Biochemical and Biophysical Research Communication</u> 214(2):403-409 (1995)
*	Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti-Sense RNA," <u>Science</u> 229:345-352 (1985)
*	Jaeger et al., "Improved Predictions of Secondary Structures for RNA," <u>Proc. Natl. Acad. Sci. USA</u> 86:7706-7710 (1989)
74.	Jarvis et al., "Optimizing the Cell Efficacy of Synthetic Ribozymes," <u>Journal of Biological Chemistry</u> 271:29107-29112 (1996)
*	Jaschke et al., "Automated Incorporation of Polyethylene Glycol into Synthetic

EXAMINER 	DATE CONSIDERED 11-7-05
--	-------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
	Applicant: Pavco et al.	
	Filing Date: November 13, 2003	Group:

Se	Oligonucleotides," <u>Tetrahedron Letters</u> 34:301-304 (1993)
75.	Jayasena, "Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics," <u>Clinical Chemistry</u> 45:1628-1650 (1999)
*	Jeffries and Symons, "A Catalytic 13-mer Ribozyme," <u>Nucleic Acids Research</u> 17:1371-1377 (1989) (also referred to as Jefferies)
*	Jellinek et al., "Inhibitions of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994)
76.	Joliet-Riant and Tillement, "Drug transfer across the blood-brain barrier and improvement of brain delivery," <u>Fundam. Clin. Pharmacol.</u> 13:16-26 (1999)
*	Joyce et al., "Amplification, mutation and selection of catalytic RNA," <u>Gene</u> 82:83-87 (1989)
*	Joyce, "Directed Molecular Evolution," <u>Scientific American</u> 267:90-97 (1992)
77.	Karpeisky et al, "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," <u>Tetrahedron Letters</u> 39:1131-1134 (1998)
*	Kashani-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme," <u>Antisense Research & Development</u> 2:3-15 (1992)
*	Kim and Cech, "Three-dimensional model of the active site of the self-splicing rRNA precursor of <i>Tetrahymena</i> ," <u>Proc. Natl. Acad. Sci. USA</u> 84:8788-8792 (1987)
*	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <u>Nature</u> 362:841-844 (1993)
*	Koch et al., "Vascular Endothelial Growth Factor: A Cytokine Modulating Endothelial Function in Rheumatoid Arthritis," 1994 <u>J. Immunol.</u> 152, 4149
*	Kore, et al., "Sequence specificity of the hammerhead ribozyme revisited; the NIH rule", <u>Nucleic Acids Research</u> , 26(18):4116-4120 (1998).
K	Kumar and Ellington, "Artificial evolution and natural ribozymes," <u>FASEB J.</u> 9:1183-1195 (1995)

EXAMINER <i>Patricia E. Ford</i>	DATE CONSIDERED 11-7-05
---	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Pavco et al.	
		Filing Date: November 13, 2003	Group:


78.	Kusser, "Chemically modified nucleic acid aptamers for in vitro selections: evolving evolution," <i>Reviews in Molecular Biotechnology</i> 74:27-38 (2000)
*	Lasic and Needham "The 'Stealth' Liposome: A Prototypical Biomaterial," <i>Chemical Reviews</i> 95:2601-2627 (1995)
79.	Lasic and Papahadjopoulos, "Liposomes Revisited," <i>Science</i> 267:1275-1276 (1995)
*	Lepri et al., "Effect of Low Molecular Weight Heparan Sulphate on Angiogenesis in the Rat Cornea after Chemical Cauterization," <i>Journal of Ocular Pharmacology</i> 10:273-281 (1994)
*	L'Huillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in α -Lactalbumin mRNA Levels in C1271 Mouse," <i>EMBO J.</i> 11:4411-4418 (1992)
*	Li and Altman, "Cleavage by RNase P of gene N mRNA reduces bacteriophage λ burst size," <i>Nucleic Acids Research</i> 24:835-842 (1996)
*	Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," <i>Methods Enzymol.</i> 217:47-66 (1993)
*	Limbach et al., "Summary: the modified nucleosides of RNA," <i>Nucleic Acids Research</i> 22(12):2183-2196 (1994)
80.	Lin and Matteucci, "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acid," <i>J. Am. Chem. Soc.</i> 120:8531-8532 (1998)
81.	Lin et al., "Policing rogue genes," <i>Nature</i> , 402, 128-129 (1999)
*	Lisiewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 90:8000-8004 (1993)
*	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <i>J. Biol. Chem.</i> 270(42):24864-24870 (1995)
*	Long and Uhlenbeck, "Kinetic characterization of intramolecular and intermolecular hammerhead RNAs with stem II deletions," <i>Proc. Natl. Acad. Sci. USA</i> 91:6977-6981 (1994)

EXAMINER 	DATE CONSIDERED 11-7-05
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Pavco et al.	
		Filing Date: November 13, 2003	Group:


SE	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach," <u>Biochemistry</u> 32:1751-1758 (1993)
	*	Ma et al., "Design and Synthesis of RNA Miniduplexes via a Synthetic Linker Approach. 2. Generation of Covalently Closed, Double-Stranded Cyclic HIV-1 TAR RNA Analogs with High Tat-Binding Affinity," <u>Nucleic Acids Research</u> 21:2585-2589 (1993)
	82.	Maher et al., "Kinetic Analysis of Oligodeoxyribonucleotide-Directed Triple-Helix Formation on DNA," <u>Biochemistry</u> 29:8820-8826 (1990)
	*	Mathews et al., "A Receptor Tyrosine Kinase cDNA Isolated from a Population of Enriched Primitive Hematopoietic cells and Exhibiting Close Genetic Linkage to c-kit," 1991, <u>Proc. Natl. Acad. Sci., USA</u> , 88, 9026
	*	McCurdy et al., "Deoxyoligonucleotides with Inverted Polarity: Synthesis and Use in Triple-Helix Formation" <u>Nucleosides & Nucleotides</u> 10:287-290 (1991)
	*	McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," <u>Proc. Natl. Acad. Sci. USA</u> 83:399-403 (1986)
	83.	McLaren et al., "Vascular Endothelial Growth Factor (VEGF) Concentrations are Elevated in Peritoneal Fluid of Women with Endometriosis," <u>Human Reproduction</u> 11:220-223 (1996)
	84.	McLaren et al., "Vascular Endothelial Growth Factor is Produced by Peritoneal Fluid Macrophages in Endometriosis and Is Regulated by Ovarian Steroids," <u>J. Clin. Invest.</u> 98:482-489 (1996)
	85.	McLaren, "Vascular Endothelial Growth Factor and Endometriotic Angiogenesis," <u>Human Reproduction Update</u> 6:45-55 (2000)
	86.	Mesmaeker et al, "Novel Backbone Replacements for Oligonucleotides," <u>American Chemical Society</u> , pp. 24-39 (1994)
SE	*	Michels and Pyle, "Conversion of a Group II Intron into a New Multiple-Turnover Ribozyme that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and Structure/Function Relationships," <u>Biochemistry</u> 34:2965-2977 (1995)

EXAMINER 	DATE CONSIDERED 10-7-05
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant:	
		Pavco et al.	
		Filing Date:	Group:
		November 13, 2003	


87.	Millauer et al., "Glioblastoma growth inhibited <i>in vivo</i> by a dominant-negative Flk-1 mutant," <i>Letters to Nature</i> 367:576-579 (1994)
*	Millauer, "High Affintiy VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <i>Cell</i> 72:835-846 (1993)
*	Miller et al., "Vascular Endothelial Growth Factor/Vascular Permeability Factor is Temporally and Spatially Correlated with Ocular Angiogenesis in a Primate Model," 1994 <i>Am. J. Pathol.</i> 145, 574
88.	Milligan and Uhlenbeck, "Synthesis of Small RNAs Using T7 RNA Polymerase," <i>Methods Enzymol.</i> 180:51-62 (1989)
89.	Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays," <i>Nature Biotechnology</i> 15:537-541 (1997)
90.	Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," <i>Science</i> 256:992-996 (1992)
*	Mukhopadhyay et al., "Antisense Regulation of Oncogenes in Human Cancer," <i>Critical Reviews in Oncogenesis</i> 7:151-190 (1996)
*	Nakamaye and Eckstein, "AUA-Cleaving Hammerhead Ribozymes: Attempted Selection for Improved Cleavage," <i>Biochemistry</i> 33:1271-1277 (1994)
*	Nathans and Smith, "Restriction Endonucleases in the Analysis and Restructuring of DNA Molecules," <i>Ann. Rev. Biochem.</i> 44:273-293 (1975)
*	Neufeld et al., "Vascular Endothelial Growth Factor and Its Receptors," <i>Progress in Growth Factor Research</i> 5:89-97 (1994)
91.	Noonberg et al., <i>In vivo</i> generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation," <i>Nucleic Acids Research</i> 22(14):2830-2836 (1994)
*	Norrby, "Angiogenesis: new aspects relating to its initiation and control," <i>APMIA</i> 105:417-437 (1997)
*	Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-

EXAMINER		DATE CONSIDERED	11-7-05
----------	---	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Pavco et al.	
		Filing Date: November 13, 2003	Group:

		Gun' Type Ribozyme-trimming Plasmid," <u>Nucleic Acids Symp. Ser. 27:15-16 (1992)</u>
	*	Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," <u>Proc. Natl. Acad. Sci. USA 89:10802-10806 (1992)</u>
	*	Oku et al., "Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography," <u>Biochimica et Biophysica Acta 1238:86-90 (1995)</u>
	*	Ono et al., "DNA Triplex Formation of Oligonucleotide Analogues Consisting of Linker Groups and Octamer Segments That Have Opposite Sugar-Phosphate Backbone Polarities," <u>Biochemistry 30:9914-9921 (1991)</u>
	*	O'Reilly et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <u>Cell 79:315-328 (1994)</u>
	*	Orgel, "Selection <i>in vitro</i> ," <u>Proc. R. Soc. London B. 205:435-442 (1979)</u>
	*	Ormerod et al., "Effects of Altering the Eicosanoid Precursor Pool on Neovascularization and Inflammation in the Alkali-burned Rabbit Cornea," <u>American Journal of Pathology 137:1243-1252 (1990)</u>
	*	Pandey et al., "Role of B61, the Ligand for the Eck Receptor Tyrosine Kinase, in TNF- α -Induced Angiogenesis," <u>Science 268:567-569 (1995)</u>
	92.	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier <i>in vivo</i> ," <u>Proc. Natl. Acad. Sci. USA 92:5592-5596 (1995)</u>
	*	Passaniti et al., "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," <u>Laboratory Investigation 67:519-528 (1992)</u>
	93.	Peel and Klein, "Adeno-associated virus vectors: activity and applications in the CNS," <u>Journal of Neuroscience Methods 98:95-104 (2000)</u>
	*	Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," <u>Nature 344:565-567 (1990)</u> (often mistakenly listed as Perrault)
	*	Perrotta and Been, "Cleavage of Oligoribonucleotides by a Ribozyme Derived from the

EXAMINER 	DATE CONSIDERED 11-7-05
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.












FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant:	
		Pavco et al.	
		Filing Date:	Group:
		November 13, 2003	


94.	Hepatitis δ Virus RNA Sequence," <u>Biochemistry</u> 31:16-21 (1992)
94.	Peterson et al., "Future Prospects of Gene Therapy for Treating CNS Diseases," <u>Central Nervous System Diseases</u> Chapter 24:485-508 (2000)
*	Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," <u>Science</u> 253:314-317 (1991)
95.	Pierce et al., "Regulation of Vascular Endothelial Growth Factor by Oxygen in a Model of Retinopathy of Prematurity," <u>Arch Ophthalmol</u> 114:1219-1228 (1996)
*	Pierce et al., "Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization," <u>Proc. Natl. Acad. Sci. USA</u> 92:905-909 (1995)
96.	Plate, "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gliomas <i>in vivo</i> ," <u>Nature</u> 359:845-848 (1992)
97.	Player and Torrence, "The 2-5A System: Modulation of Viral and Cellular Processes Through Acceleration of RNA Degradation," <u>Pharmacol Ther.</u> 78:55-113 (1998)
*	Plouet et al., "Isolation and Characterization of a Newly Identified Endothelial Cell Mitogen Produced by AtT-20 Cells," 1989 <u>EMBO J.</u> 8, 3801
98.	Praseuth et al., "Triple helix formation and the antigene for sequence-specific control of gene expression," <u>Biochimica et Biophysica Acta</u> 1489:181-206 (1999)
99.	Quereda et al., "Individual and Combined Effects of Triptoreline and Gestrinone on Experimental Endometriosis in Rats," <u>European Obstetrics & Gynecology and Reproductive Biology</u> 67:35-40 (1996)
*	Richardson and Schepartz, "Tethered Oligonucleotide Probes. A Strategy for the Recognition of Structured RNA," <u>J. Am. Chem. Soc.</u> 113:5109-5111 (1991)
*	Robinson et al., "Oligodeoxynucleotides Inhibit Retinal Neovascularization in a Murine Model of Proliferation Retinopathy," <u>Proc. Natl. Acad. Sci. USA</u> 93: 4851- 4856 (1996)
*	Rossi et al., "Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems," <u>Aids Research and Human Retroviruses</u> 8:183-189 (1992)

EXAMINER		DATE CONSIDERED	11-7-05
----------	--	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant:	
		Pavco et al.	
		Filing Date:	Group:
		November 13, 2003	

	*	Santoro and Joyce, "A general purpose RNA-cleaving DNA enzyme," <u>Proc. Natl. Acad. Sci. USA</u> 94:4262-4266 (1997)
	100.	Santoro et al., "Mechanism and Utility of an RNA-Cleaving DNA Enzyme," <i>Biochemistry</i> 37:13330-13342 (1998)
	101.	Santoro et al., "RNA Cleavage by a DNA Enzyme with Extended Chemical Functionality," <i>J. Am. Chem. Soc.</i> 122:2433-2439 (2000)
	*	Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" <u>Science</u> 247:1222-1225 (1990)
	*	Saville and Collins, "A Site-Specific Self-Cleavage Reaction Performed by a Novel RNA In <i>Neurospora</i> Mitochondria," <i>Cell</i> 61:685-696 (1990)
	*	Saville and Collins, "RNA-Mediated Ligation of Self-Cleavage Products of a <i>Neurospora</i> Mitochondrial Plasmid Transcript," <u>Proc. Natl. Acad. Sci. USA</u> 88:8826-8830 (1991)
	*	Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," <u>Proc. Natl. Acad. Sci. USA</u> 88:10591-10595 (1991)
	*	Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using β -cyanoethyl protected ribonucleoside phosphoramidites," <u>Nucl Acids Res.</u> 18:5433-5441 (1990)
	102.	Schmajuk et al., "Antisense Oligonucleotides with Different Backbones," <i>The Journal of Biological Chemistry</i> 274:21783-21789 (1999)
	103.	Schroeder et al., "Diffusion Enhancement of Drugs by Loaded Nanoparticles in Vitro," <i>Prog. Neuro-Psychopharmacol. & Biol. Psychiat.</i> 23:941-949 (1999) [sometimes cited by RPI as <i>Prog Neuropsychopharmacol Biol Psychiatry</i> 23:941-949, 1999]
	*	Seela and Kaiser, "Oligodeoxyribonucleotides containing 1,3-propanediol as nucleoside substitute," <u>Nucleic Acids Research</u> 15:3113-3129 (1987)

EXAMINER		DATE CONSIDERED	11-7-05
----------	---	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-325-A (400/047)

Serial No.

10/712,633

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Pavco et al.

Filing Date:

November 13, 2003

Group:

	*	Senger et al., "Vascular permeability factor (VPF, VEGF) in tumor biology," <i>Cancer and Metastasis Reviews</i> 12:303-324 (1993)
104.		Shabarova et al., "Chemical ligation of DNA: The first non-enzymatic assembly of a biologically active gene," <i>Nucleic Acids Research</i> 19:4247-4251 (1991)
	*	Shalaby et al., "Failure of Blood-island Formation and Vasculogenesis in Flk-1-deficient Mice," 1995 <i>Nature</i> 376, 62
106.		Sharkey et al., "Vascular Endothelial Growth Factor Expression in Human Endometrium is Regulated by Hypoxia," <i>The Journal of Clinical Endocrinology & Metabolism</i> 85:402-409 (2000)
107.		Sharp et al., "RNAi and double-strand RNA," <i>Genes & Development</i> , 13:139-141 (1999)
108.		Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <i>Oncogene</i> 5:519-524 (1990)
109.		Shifren et al., "Ovarian Steroid Regulation of Vascular Endothelial Growth Factor in the Human Endometrium: Implications for Angiogenesis during the Menstrual Cycle and in the Pathogenesis of Endometriosis," <i>The Journal of Clinical Endocrinology & Metabolism</i> 81:3112-3118 (1996)
	*	Shweiki et al., "Patterns of Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Mice Suggest a Role in Hormonally Regulated Angiogenesis," 1993 <i>Clin. Invest.</i> 91: 2235-2243
110.		Silverman et al., "Selective RNA Cleavage by Isolated RNase L Activated with 2-5A Antisense Chimeric Oligonucleotides," <i>Methods in Enzymology</i> 313:522-533 (1999)
	*	Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?" <i>Science</i> 261:1004-1288 (1993)
111.		Stein et al., "A Specificity Comparison of Four Antisense Types: Morpholino, 2'-O-Methyl RNA, DNA, and Phosphorothioate DNA," <i>Antisense & Nucleic Acid Drug Development</i> 7:151-157 (1997)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Pavco et al.	
		Filing Date: November 13, 2003	Group:

112.	Stoeckemann et al., "Effects of the Progesterone Antagonists Onapristone (ZK 98 299) and ZK 136 799 on Surgically Induced Endometriosis in Intact Rats," <u>Human Reproduction</u> 10:3264-3271 (1995)
113.	Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found," <u>Molecular Biology</u> , Vol. 286, No. 5441, p. 886 (1999) [sometimes mistakenly referred to as being published in <u>Science</u>]
114.	Strobel and Dervan, "Site-Specific Cleavage of a Yeast Chromosome by Oligonucleotide-Directed Triple-Helix Formation," <u>Science</u> 249:73-75 (1990)
115.	Sullenger et al., "Overexpression of TAR Sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication," <u>Cell</u> 63:601-608 (1990)
116.	Sun, "Technology evaluation: SELEX, Giliad Sciences Inc," <u>Current Opinion in Molecular Therapeutics</u> 2:100-105 (2000)
*	Szostak and Ellington, "Ch. 20 - In Vitro Selection of Functional RNA Sequences," in <u>The RNA World</u> , edited by Gesteland and Atkins, Cold Spring Harbor Laboratory Press, pp. 511-533 (1993)
*	Szostak, " <u>In Vitro Genes</u> ," <u>TIBS</u> 17:89-93 (1993)
*	Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both <i>in vitro</i> in place of run-off and (G)-free transcriptions and <i>in vivo</i> as multi-sequences transcription vectors," <u>Nucleic Acids Research</u> 19:5125-5130 (1991)
*	Takahashi et al., "Markedly Increased Amounts of Messenger RNAs for Vascular Endothelial Growth Factor and Placenta Growth Factor in Renal Cell Carcinoma Associated with Angiogenesis," <u>Cancer Research</u> 54:4233-4237 (1994)
*	Takeshita et al., "Therapeutic Angiogenesis: A Single Intraarterial Bolus of Vascular Endothelial Growth Factor Augments Revascularization in a Rabbit Ischemic Hind Limb Model," 1995 <u>J. Clin. Invest.</u> 93, 662 Corrected from Specification
*	Tang et al., "Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection," <u>RNA</u> 3:914-925 (1997)

EXAMINER		DATE CONSIDERED	11-7-05
----------	---	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-325-A (400/047)

Serial No.

10/712,633

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



Applicant:

Pavco et al.

Filing Date:

November 13, 2003

Group:

	*	Terman <i>et al.</i> , "Identification of a New Endothelial Cell Growth Factor Receptor Tyrosine Kinase," 1991 <i>Oncogene</i> 6, 1677
	*	Thompson <i>et al.</i> , "Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter," <i>Nucleic Acids Research</i> 23:2259-2268 (1995)
	*	Torrence <i>et al.</i> , "Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense chimera," <i>Proc. Natl. Acad. Sci. USA</i> 90:1300-1304 (1993)
	*	Turner <i>et al.</i> , "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," <i>J. Am. Chem. Soc.</i> 109:3783-3785 (1987)
	*	Turner <i>et al.</i> , "Improved Parameters for Prediction of RNA Structure," <i>Cold Spring Harbor Symposia on Quantitative Biology Volume LII</i> , pp. 123-133 (1987)
	117.	Tuschl <i>et al.</i> , "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," <i>Genes & Development</i> 13:3191-3197 (1999)
	118.	Tyler <i>et al.</i> , "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," <i>Proc. Natl. Acad. Sci. USA</i> 96:7053-7058 (1999)
	119.	Tyler <i>et al.</i> , "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," <i>FEBS Letters</i> 421:280-284 (1998)
	*	Uhlenbeck, "A Small Catalytic Oligoribonucleotide," <i>Nature</i> 328:596-600 (1987)
	120.	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," <i>Chemical Reviews</i> 90:544-584 (1990)
	*	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," <i>TIBS</i> 17:334-339 (1992) (Corrected from Specification)
	*	Usman and McSwiggen, "Ch. 30 - Catalytic RNA (Ribozymes) as Drugs," <i>Annual Reports in Medicinal Chemistry</i> 30:285-294 (1995)
	*	Usman <i>et al.</i> , "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support:

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

02-325-A (400/047)

Serial No.

10/712,633

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Pavco et al.

Filing Date:

November 13, 2003

Group:

		Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an <i>Escherichia coli</i> Formylmethionine tRNA," <u>J. Am. Chem. Soc.</u> 109:7845-7854 (1987)
	*	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," <u>Nucleic Acids Symposium Series</u> 31:163-164 (1994)
	121.	Usman et al., "Hammerhead ribozyme engineering," <u>Current Opinion in Structural Biology</u> 1:527-533(1996)
	*	Vaish et al., "Isolation of Hammerhead Ribozymes with Altered Core Sequences by <i>in Vitro</i> Selection," <u>Biochemistry</u> 36:6495-6501 (1997)
	*	Vaisman et al., "Characterization of the Receptors for Vascular Endothelial Growth," 1990 <u>J. Biol. Chem.</u> 265, 19461
	*	Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," <u>Nucleic Acids Research</u> 21:3249-3255 (1993)
	122.	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," <u>Annu. Rev. Biochem.</u> 67:99-134 (1998)
	123.	Warashina, et al., "Extremely High and Specific Activity of DNA Enzymes in Cells with a Philadelphia Chromosome, <u>Chemistry & Biology</u> , 6(4):237-250 (1999)
	124.	Waterhouse et al., "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA," <u>Proc. Natl. Acad. Sci. USA</u> , 95, 13959-13964 (1998)
	*	Weckbecker et al., 1992, <i>Angiogenesis: Key principles-Science-Technology-Medicine</i> , ed R. Steiner)
	*	Weerasinghe et al., "Resistance to Human Immunodeficiency Virus Type 1 (HIV-1) Infection in Human CD4 ⁺ Lymphocyte-Derived Cell Lines Conferred by Using Retroviral Vectors Expressing an HIV-1 RNA-Specific Ribozyme," <u>Journal of Virology</u> 65:5531-5534 (1994)
	125.	Wellstein and Czubayko, "Inhibition of Fibroblast Growth Factors," <u>Breast Cancer Research and Treatment</u> 38:109-119 (1996)

EXAMINER

DATE CONSIDERED

11-7-05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
			Applicant: Pavco et al.	
			Filing Date: November 13, 2003	Group:

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

126.	Werner and Uhlenbeck, "The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis," <u>Nucleic Acids Research</u> 23:2092-2096 (1995)
*	Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," <u>Nucleic Acids Research</u> 23(14):2677-2684 (1995)
127.	Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," <u>Methods in Molecular Biology</u> 74:59-69 (1997)
128.	Woolf et al., "Specificity of Antisense Oligonucleotides <i>in vivo</i> ," <u>Proc. Natl. Acad. Sci. USA</u> 89:7305-7309 (1992)
129.	Wu-Pong, "Oligonucleotides: Opportunities for Drug Therapy and Research," <u>BioPharm</u> pp20-33 (1994)
*	Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," <u>Proc. Natl. Acad. Sci. USA</u> 90:6340-6344 (1993)
*	Zaug et al., "The <i>Tetrahymena</i> Ribozyme Acts Like an RNA Restriction Endonuclease," <u>Nature</u> 324:429-433 (1986)
*	Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase," <u>Mol. Cell. Biol.</u> 10:4529-4537 (1990)
*	Ziche et al., "Angiogenesis Can Be Stimulated or Repressed <i>In vivo</i> by a Change in GM3:GD3 Ganglioside Ratio" 1992 <u>Lab. Invest.</u> 67: 711-715

EXAMINER 	DATE CONSIDERED 11-7-05
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.